Annexon, Inc. Stock Price, News & Analysis

Annexon (Nasdaq: ANNX) announced interim results from its ongoing Phase 2 trial of ANX005 for Huntington's disease (HD), showing encouraging safety and efficacy. The treatment demonstrated full target engagement of C1q in cerebrospinal fluid, with over 50% of evaluable patients maintaining clinical function. In patients with excess complement activity, 75% showed improvement in clinical measures. No serious adverse infections or deaths were reported. Full data is expected in Q2 2022, with plans for a Phase 3 trial pending results.

Annexon, a clinical-stage biopharmaceutical company (Nasdaq: ANNX), announced that its CEO, Douglas Love, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 3:45 p.m. ET. The presentation will focus on their innovative complement medicines targeting autoimmune and neurodegenerative disorders. A live webcast will be available on their website, with a replay accessible for 30 days post-event.

Annexon's pipeline includes product candidates like ANX005, ANX007, and ANX009, designed to disrupt the C1q pathway.

Annexon announced positive safety and dose-response results from its Phase 1 trial of ANX009, designed to block C1q in autoimmune diseases. The study, involving 48 healthy volunteers, showed no serious adverse events and effective C1q inhibition, supporting further trials. Additionally, preclinical findings presented at the ASH Annual Meeting indicated the classical complement pathway's role in warm autoimmune hemolytic anemia (wAIHA), with ongoing evaluations of ANX005 in a Phase 2 trial for this condition.

Annexon reported a net loss of $35.6 million or $0.93 per share for Q3 2021, compared to $15.6 million or $0.77 per share year-over-year. As of September 30, 2021, the company had $271.4 million in cash and investments, supporting operations into 2024. The FDA granted Orphan Drug designation for ANX005, aimed at treating Huntington's disease. The company is advancing three clinical-stage candidates in five trials, with initial data from ANX005 expected in Q4 2021. The leadership team has strengthened with new appointments, enhancing the company's research efforts.

Annexon, a clinical-stage biopharma company, has appointed Ted Yednock as Chief Innovation Officer and Larry Mattheakis as Chief Scientific Officer. Yednock, previously Chief Scientific Officer since 2013, will focus on strengthening scientific collaborations while remaining on the executive committee. Mattheakis brings extensive drug development experience from Protagonist Therapeutics, aiming to enhance Annexon’s therapeutic pipeline for complement-mediated diseases. The company is currently progressing three drug candidates across seven clinical trials, focusing on autoimmune, neurodegenerative, and ophthalmic disorders.

On September 23, 2021, Annexon (Nasdaq: ANNX), a biopharmaceutical company, announced that its CEO, Douglas Love, will speak at the 2021 Cantor Virtual Global Healthcare Conference on September 30, 2021, at 12:40 p.m. ET. The event will be available via a live webcast on Annexon's Investors page and will be archived for 30 days post-presentation. Annexon focuses on developing complement medicines for autoimmune, neurodegenerative, and ophthalmic disorders, with a pipeline that includes innovative products like ANX005, ANX007, and ANX009.

On September 20, 2021, Annexon (Nasdaq: ANNX) announced its upcoming virtual C1q Series event scheduled for September 27, 2021, at 10:00 a.m. ET. This event will focus on the company's neurodegeneration franchise and will include presentations from the executive team and key opinion leaders. A live webcast will be accessible through the Investors section of annexonbio.com. Annexon specializes in developing complement medicines for autoimmune, neurodegenerative, and ophthalmic disorders, leveraging its technology to target diseases caused by C1q activation.

Annexon (Nasdaq: ANNX) announced its second quarter 2021 financial results and business updates, highlighting progress in its autoimmune and neurodegenerative therapeutic franchises. The company advanced its clinical candidate ANX009 in treatment of autoimmune diseases and reported data from ANX005 trials in Huntington’s and Amyotrophic Lateral Sclerosis. Financially, Annexon reported a net loss of $31.3 million for Q2 2021, up from $12.2 million in Q2 2020, with R&D expenses rising to $24.6 million. The company appointed William D. Waddill to its Board, enhancing its strategic capabilities.

Annexon has announced advancements in its autoimmune pipeline, moving ANX009 into a Phase 1b program for Lupus Nephritis and expanding ANX005 to a Phase 2 trial for Multifocal Motor Neuropathy (MMN). ANX009 was well-tolerated in a Phase 1 trial and demonstrated robust C1q inhibition, leading to its selection for Lupus Nephritis patients. Meanwhile, ANX005 is expected to address unmet needs in MMN, which is characterized by progressive muscle weakness due to immune-mediated nerve damage. The company is poised to enhance its C1q inhibitor portfolio, targeting significant autoimmune conditions.